𝗗𝗮𝗻𝗼𝗻𝗲'𝘀 𝗱𝘂𝗮𝗹-𝘁𝗿𝗮𝗰𝗸 𝗠&𝗔.

𝗧𝘄𝗼 𝗱𝗲𝗮𝗹𝘀. 𝗧𝘄𝗼 𝗹𝗼𝗴𝗶𝗰𝘀.

Huel: €1B. Future bet.

Mead Johnson: multi-billion. Consolidation play.

Most FMCG companies can do one or the other.

Danone is doing both.

𝗧𝗵𝗲 𝗛𝘂𝗲𝗹 𝗹𝗼𝗴𝗶𝗰:

→ Small enough to absorb. Big enough to matter.

→ Complete nutrition is a real category now

→ GLP-1 tailwind is accelerating demand

→ DTC capability Danone doesn't have

𝗧𝗵𝗲 𝗠𝗲𝗮𝗱 𝗝𝗼𝗵𝗻𝘀𝗼𝗻 𝗹𝗼𝗴𝗶𝗰:

→ Enfamil gives Danone the US infant formula position it lacks

→ Speciality nutrition with Nutramigen fits the medical pivot

→ Birth rates are declining. Scale becomes necessary

→ Reckitt wants out. Danone can absorb.

𝗪𝗵𝘆 𝗗𝗮𝗻𝗼𝗻𝗲 𝗰𝗮𝗻 𝗱𝗼 𝗯𝗼𝘁𝗵:

€2.8B free cash flow.

4.5% like-for-like growth in 2025.

Balance sheet capacity for large M&A.

The financial room exists.

Most competitors don't have it.

𝗧𝗵𝗲 𝗿𝗶𝘀𝗸𝘀 𝗮𝗿𝗲 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁 𝘁𝗼𝗼:

Huel: integration complexity. Can Danone preserve speed and authenticity?

Mead Johnson: NEC litigation liabilities. Regulatory hurdles in US and China.

Different deal sizes.

Different risk profiles.

Same portfolio thesis.

𝗧𝗵𝗲 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰 𝘀𝗶𝗴𝗻𝗮𝗹:

Danone is building a nutrition portfolio on two tracks:

1. Small bets on emerging demand spaces [Huel, complete nutrition]

2. Large consolidation in mature categories [MJ, infant formula]

This is portfolio construction with optionality.

Not all-in on one direction.

How many FMCG companies have the balance sheet to run both tracks?